MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs.
The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS).
With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Ownership
BioCatalyst is an international group of scientific and business managers who partner with scientific teams to create market driven, sustainable biotech companies. We are a company focused on the transition from research to commercialization. Typical partners include academic scientists, early stage biotech companies who require accelerated sales, major bioscience research centers who seek the creation of multiple sustainable biotech companies on a continuing basis, and the venture arm of pharmaceutical companies who have specific startup objectives. BioCatalyst currently has offices in New York (NY), West Palm Beach (FL), and Cambridge (UK).
http://www.biocatalystintl.com
The Ballast Point partners have more than 60 years of combined experience investing in and building private, high-growth companies in a number of industries, including communications, health care, technology, manufacturing, consumer products, business services and specialty retail. We seek to make equity investments ranging in size from $1.0 million to $5.0 million, which result in Ballast Point Ventures owning minority positions in businesses owned and operated by outstanding management teams.